SPRYNasdaqPharmaceutical PreparationsFiscal year ends December 31
ARS Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$4.23+0.21 (+5.22%)
Close on Oct 19, 2026
- Market cap
- $420.09M
- P/E (TTM)
- –
- Dividend yield
- –
ARS Pharmaceuticals, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q4 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $95.29M | $81.88M | $72.19M | $58.55M | $27.82M | $15.02M | $7.26M | $568.00K | $0 | $0 | 81.5% | +242.6% |
| Revenue under supply agreements | $12.18M | $5.11M | $2.37M | $1.83M | $688.00K | $365.00K | $365.00K | – | – | – | 10.4% | +1670.1% |
| Revenue under collaboration agreements [Member] | $9.46M | $12.00M | $9.72M | $82.39M | $83.83M | $81.74M | $81.53M | $2.00M | $500.00K | $30.00K | 8.1% | -88.7% |
By region
From the segment and revenue-disaggregation notes of ARS Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.